OrbiMed Advisors »

Taysha Gene Therapies shares owned by OrbiMed Advisors

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by OrbiMed Advisors from 13F filings

Historical chart of OrbiMed Advisors investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by OrbiMed Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $14M 2.0M 6.81

More positions owned by OrbiMed Advisors

Edgewise Therapeutics (EWTX)
Enliven Therapeutics (ELVN)
Eli Lilly & Co. (LLY)
Mbx Biosciences (MBX)
Sinovac Biotech SHS
Astrazeneca Ord (AZN)
Structure Therapeutics Sponsored Ads (GPCR)
Sionna Therapeutics (SION)
Corvus Pharmaceuticals (CRVS)
Arrivent Biopharma (AVBP)
Abivax Sa Sponsored Ads Call Option (ABVX)
Guardant Health (GH)
Argenx Se Sponsored Adr (ARGX)
Merck & Co (MRK)
Uniqure Nv SHS (QURE)

View all positions for OrbiMed Advisors

Top funds holding Taysha Gene Therapies

venBio Select Advisor
RA Capital Management
Goldman Sachs Group
BlackRock
Vestal Point Capital
Morgan Stanley
Rtw Investments
FMR
Vanguard Capital Management
State Street Corporation
Siren
Octagon Capital Advisors
Geode Capital Management
Polar Capital Holdings
MPM Oncology Impact Management

View all funds holding Taysha Gene Therapies